As shown in experimental animal tumor models, targeting the interaction of galectin-3 with N-glycosylated ectodomain MUC16 expressed on serous ovarian cancer cells by high-affinity antibody is suggested as a potential cancer therapeutic strategy (26, 27). This evidence concerns the gene LGALS3 and cancer.